A matter of motion or an emotional matter? Management of depression in Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 5, Issue 6, 2005, Pages 803-810

  Lagopoulos, Jim ^a,b,c,d   Malhi, Gin S ^a,b,c   Ivanovski, Belinda ^a,b   Cahill, Catherine M ^a,b   Morris, John G L ^d,e  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c BLACK DOG INSTITUTE   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e University of Sydney   (Australia)

Author keywords

Antidepressant; Depression; Electroconvulsive therapy; Parkinson's disease; Psychomotor slowing; Serotonin; Transcranial magnetic stimulation

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DOXEPIN; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; PROTRIPTYLINE; QUETIAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EMOTION; EPIDEMIOLOGICAL DATA; EXTRAPYRAMIDAL SYMPTOM; GENETICS; HUMAN; KINESIOTHERAPY; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RATING SCALE; RELAXATION TRAINING; REVIEW; SCREENING; SIDE EFFECT; SYMPTOM; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSION; EMOTIONS; EXPERT TESTIMONY; HUMANS; MOTION; PARKINSON DISEASE;

EID: 27944475991     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.6.803     Document Type: Review

References (95)

1. Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14, 223-236 (2002).
2. Aarsland D, Larsen JP, Lim NG et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67, 492-496 (1999).
3. Stefurak TM. Cortico-limbic dysfunction in depression: converging fingings in basal ganglia disease and primary affective disorders. In: Mental and Behavioral Dysfunction in Movement Disorders. Bedard A, Agid Y, Chouinard S, Fahn S, Korczyn A, Lespérance P (Eds). Humana Press, NJ, USA (2003).
4. Lauterbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr. Clin. North Am. 27, 801-825 (2004).
5. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci. 17, 214-220 (2005).
6. Azmitia EGP. The serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. In: Myoclonus. Fahn S (Ed.). Raven Press, NY, USA (1985).
7. Jellinger K. Overview of morphological changes in Parkinson's disease. IN Yahr MB (Ed.). Advances in Neurology: Parkinson's Disease. Raven Press, NY, USA (1986).
8. Rihmer Z, Seregi K, Rihmer A. Parkinson's disease and depression. Neuropsychopharmacol. Hung. 6, 82-85 (2004).
9. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch. Neurol. 53, 175-179 (1996).
10. Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. Br. Med. J. 320, 1287-1288 (2000).
11. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 187-196(2001).
12. Leentjens AF, Marinus J, Van Hilten JJ, Lousberg R, Verhey FR. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J. Neuropsychiatry Clin. Neurosci. 15, 74-77 (2003).
13. Naarding P, Leentjens AF, van Kooten F, Verhey FR. Disease-specific properties of the Rating Scale for Depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 14, 329-334 (2002).
14. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 16, 178-183 (2003).
15. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat. Disord. 10, 23-28 (2003).
16. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8, 193-197 (2002).
17. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 28, 35-38 (1999).
18. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov. Disord. 15, 216-223 (2000).
19. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36, 1130-1133(1986).
20. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG. Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol. Neurosurg. Psychiatry 53, 597-602 (1990).
21. Dooneief G. Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol. 49, 305-307 (1992).
22. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry 49, 381-389(1986).
23. Cummings JL. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149, 443-454 (1992).
24. Schuurman AG, van den Akker M, Ensinck KT et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 58, 1501-1504 (2002).
25. Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15, 669-677 (2000).
26. Todes CJ, Lees AJ. The pre-morbid personality of patients with Parkinson's disease. J Neurol Neurosurg. Psychiatry 48, 97-100 (1985).
27. Robertson M. Depression in neurological disorders. In: Depression and Physical Illness. Robertson MK, Cornelius LE (Eds). John Wiley and Sons, Chichester, UK (1997).
28. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J. Geriatr. Psychiatry Neurol. 3, 3-9 (1990).
29. Leentjens AF, Lousberg R, Verhey FR, Markers for depression in Parkinson's disease. Acta Psychiatr. Scand. 106, 196-201 (2002).
30. Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein SE. Cognitive functions in major depression and Parkinson disease. Arch. Neurol. 54, 982-986 (1997).
31. Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC. The correlation of depression with functional activity in Parkinson's disease. J. Neurol 244, 493-498 (1997).
32. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J. Am. Geriatr. Soc. 52, 784-788 (2004).
33. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J. Nerv. Ment. Dis. 178, 27-31 (1990b).
34. Zubenko GS. Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 6, 77-93 (1992).
35. Zweig RM, Ross CA, Hedreen JC et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol. 24, 233-242 (1988).
36. Forstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P. Neurologic signs in Alzheimer's disease. Results of a prospective clinical and neuropathologic study. Arch. Neurol. 49, 1038-1042 (1992).
37. Mayberg HS, Starkstein SE, Sadzot B et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann. Neurol. 28, 57-64 (1990).
38. Rogers D. Bradyphrenia in Parkinson's disease. In: Parkinson's Disease: Neurobehavioral Aspects. Huber SC (Ed.). Oxford University Press, NY, USA, (1992).
39. Goodwin FK, Murphy DL, Brodie HK, Bunney WE Jr. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. Biol. Psychiatry 2, 341-366 (1970).
40. Korf J, van Praag HM, Schut D, Nienhuis RJ, Lakke JP. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy. Eur. Neurol. 12, 340-350 (1974).
41. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11, 58-65 (2000).
42. Lemke MR, Fuchs G, Gemende I et al. Depression and Parkinson's disease. J. Neurol. 251(Suppl. 6), 24-27 (2004).
43. Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17, 965-973 (2003).
44. Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology 34, 642-646 (1984).
45. Malhi GS, Checkley SA. Olanzapine in the treatment of psychotic depression. Br. J. Psychiatry 174, 460 (1999).
46. Malhi G, Berk M, Bourin M et al. Atypical mood stabilizers: a 'typical' role for atypical antipsychotics. Acta Psychiatr. Scand. 111, 29-38 (2005).
47. Cash R, Raisman R, Ploska A, Agid Y. High and low affinity [3H]imipramine binding sites in control and Parkinsonian brains. Eur. J. Pharmacol. 117, 71-80 (1985).
48. Backman J, Alling C, Alsen M, Regnell G, Traskman-Bendz L. Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment. Eur. Neuropsychopharmacol. 10, 341-349 (2000).
49. Van Praag HM. Depression. Lancet 2, 1259-1264 (1982).
50. Hesse S, Barthel H, Schwarz J, Sabri O, Muller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 28, 547-563 (2004).
51. Meyer JH, Houle S, Sagrati S et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry 61, 1271-1279 (2004).
52. Sargent PA, Kjaer KH, Bench CJ et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57, 174-180 (2000).
53. Becker T, Becker G, Seufert J et al. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg. Psychiatry 63, 590-596 (1997).
54. Mayeux R. Depression in the patient with Parkinson's disease. J. Clin. Psychiatry 51, 20-25 (1990).
55. Mayberg HS. Frontal lobe dysfunction in secondary depression. J. Neuropsychiatry Clin. Neurosci. 6, 428-42 (1994).
56. Jellinger KA. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 56, 1-29 (1999).
57. Murai T, Muller U, Werheid K et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 222-228 (2001).
58. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn. Behav. Neurol. 16, 193-210 (2003).
59. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 43, 1693-1697 (1993).
60. Taylor CA, Saint-Hilaire MH, Cupples LA et al. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am. J. Med. Genet. 88, 742-749 (1999).
61. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389 (2003).
62. Mossner R, Henneberg A, Schmitt A et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol. Psychiatry 6, 350-352 (2001).
63. Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J. Geriatr. Psychiatry Neurol 12, 49-52 (1999).
64. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 55, 377-382 (1992).
65. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571 (1961).
66. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol. Med. 31, 65-73 (2001).
67. Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee M, Vickrey BG. Development of quality of care indicators for Parkinson's disease. Mov Disord. 19, 136-150 (2004).
68. Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
69. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br. J. Psychiatry 167, 99-103 (1995).
70. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62 (1960).
71. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int. J. Geriatr. Psychiatry 15, 644-649 (2000).
72. Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov. Disord. 15, 1221-1224 (2000).
73. Franz M, Lemke MR, Meyer T, Ulferts J, Puhl P, Snaith RP. German version of the Snaith-Hamilton Pleasure Scale (SHAPS-D). Anhedonia in schizophrenic and depressive patients. Fortschr. Neurol. Psychiatr. 66, 407-413 (1998).
74. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov. Disord. 17, 445-454 (2002).
75. Yesavage JA. Geriatric Depression Scale. Psychopharmacol. Bull. 24, 709-711 (1988).
76. Beekman A. Diagnostic procedures in depression in Parkinson's disease: epidemiology and management. In: Mental Dysfunction in Parkinson's Disease. Wolters ESP, Berendse HW (Eds). Academic Pharmaceutical Productions, Utrecht, The Netherlands (1999).
77. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin. Neuropharmacol. 25, 318-324 (2002).
78. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression, J. Comp. Neurol. 287(3), 373-392 (1989).
79. Dell'Agnello G, Ceravolo R, Nuti A et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin. Neuropharmacol 24, 221-227 (2001).
80. Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin. Neuropharmacol 26, 142-145 (2003).
81. Andersen J, Aabro E, Gulmann N et al. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta. Neurol. Scand. 62(4), 210-219 (1980).
82. Neufeld MY, Rabey JM, Orlov E, Korczyn AD. Electroencephalographic findings with low-dose clozapine treatment in psychotic Parkinsonian patients. Clin. Neuropharmacol 19(1), 81-86. (1996).
83. Wermuth L, Sorensen PS, Timm B et al. Depression in idiopathic Parkinson's disease treated with citalopram. A placebo controlled trial. Nordic J. Psychiatry 52, 163-169 (1998).
84. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54(3), 363-375 (2003).
85. Malhi GS, Parker GB, Gladstone G, Wilhelm K, Mitchell PB. Recognizing the anxious face of depression. J. Nerv. Ment. Dis. 190, 366-373 (2002).
86. Oertel WH, Ellgring H. Parkinson's disease-medical education and psychosocial aspects. Patient Educ. Couns. 26, 71-79 (1995).
87. Fall PA, Granerus AK. Maintenance ECT in Parkinson's disease. J. Neural Transm. 106, 737-741 (1999).
88. Moellentine C, Rummans T, Ahlskog JE et al. Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci 10, 187-193 (1998).
89. Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic VS. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study. Mov. Disord. 17, 528-532 (2002).
90. Mally J, Stone TW. Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J. Neurol. Sci. 162, 179-184 (1999).
91. Manes F, Jorge R, Morcuende M, Yamada T, Paradiso S, Robinson RG. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int. Psychogeriatr. 13, 225-231 (2001).
92. Wassermann EM, Lisanby SH. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin. Neurophysiol. 112, 1367-1377 (2001).
93. Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. Self-reported mood changes following 6 months of vagus nerve stimulation in epilepsy patients. Epilepsy Behav. 2, 335-342 (2001).
94. Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res. 42, 203-210 (2000).
95. Jobe PC, Dailey JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit. Rev. Neurobiol. 13, 317-356 (1999).